Artificial Intelligence | Machine Learning | Machine Perception Exscientia | Accelerate Drug Discovery & Development


Enterprise, Biotechnology, Pharmaceuticals & Medical Product, Drug Design, Small Molecules Oxford, Oxfordshire, United Kingdom

Exscientia

Artificial Intelligence | Machine Learning | Machine Perception


Exscientia | Accelerate Drug Discovery & Development

Exscientia

Biotechnology, Pharmaceuticals & Medical Product, Drug Design, Small Molecules


Oxford, Oxfordshire, United Kingdom

We are the leading pharma tech company and the first to automate drug discovery. Our aim is to make safer, more sophisticated drugs available to all - more quickly and efficiently than ever before

At the forefront of small molecule drug discovery, We are the first company to automate drug design, surpassing conventional human endeavor. Our AI-driven systems actively learn best practices from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME, and other key criteria. From this, a selection of the best, information-rich compounds is selected for synthesis and assay.

 
 

   Total Funding: $103,671,986

   Funding Stage: Series C

   Business Stage: N/A

   Market: B2B

   Company Size: 26 to 50

   Founded: 2012

Feb 2021

  • Exscientia and the University of Oxford Announce Partnership to Develop Treatments for Alzheimer?s Disease

Nov 2018

  • Exscientia Acquired Kinetic Discovery Ltd. for an Undisclosed Amount

Oct 2017

  • Exscientia Wins Best Emerging Biotech Company Award at OBN Annual Awards 2017
 
 

Date

Round

$ Raised

Investors

04/27/2021

Series D

$225M

CMC Capital Group, CMC Capital Group, Pivotal bioVenture Partners, Pivotal bioVenture Partners, Novo Holdings, Marshall Wace, Marshall Wace, Mubadala Capital Ventures, Mubadala Capital Ventures, Laurion Capital Management, Laurion Capital Management, GT Healthcare Capital, GT Healthcare Capital, Farallon Capital Management, Farallon Capital Management, Casdin Capital, Casdin Capital, BlackRock Private Equity Partners,, BlackRock Private Equity Partners,

Date : 04/27/2021

Round: Series D

$ Raised: $225M

Investors: CMC Capital Group, CMC Capital Group, Pivotal bioVenture Partners, Pivotal bioVenture Partners, Novo Holdings, Marshall Wace, Marshall Wace, Mubadala Capital Ventures, Mubadala Capital Ventures, Laurion Capital Management, Laurion Capital Management, GT Healthcare Capital, GT Healthcare Capital, Farallon Capital Management, Farallon Capital Management, Casdin Capital, Casdin Capital, BlackRock Private Equity Partners,, BlackRock Private Equity Partners,

 

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Exscientia

 
 
 
Willem van Hoorn


Willem van Hoorn
Chief Decision Scientist

Dave Hallett


Dave Hallett
Chief Operating Officer

Adrian Schreyer


Adrian Schreyer
Chief Research Engineer

Jeremy Besnard


Jeremy Besnard
Chief Designer

Richard Bickerton


Richard Bickerton
Chief Informatics Officer

 
 

Exscientia is growing. Want to work at Exscientia? Exscientia is hiring. Join team at Exscientia

 

View All

View All AI/ML Jobs

Data Engineer

Dundee, Scotland

Computational Drug Designer

Miami, Florida

Director Computational Drug Design

Miami, Florida

Executive Director Drug Design

Miami, Florida

Join our Miami talent pool

Miami, Florida

 
 
appengine.ai

World's Most Promising AI/ML Startups